An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial.

Tetsuya Eto,Masahito Kotaka,Dai Manaka,Jun-ichi Hasegawa,Akinori Takagane,Masato Nakamura,Takeshi Kato,Yoshinori Munemoto,Fumitaka Nakamura,Hiroyuki Bandou,Hiroki Taniguchi,Makio Gamoh,Manabu Shiozawa,Takeharu Yamanaka,Tsunekazu Mizushima,Junichi Sakamoto,Shigetoyo Saji,Masaki Mori,Atsushi Ohtsu,Takayuki Yoshino

An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial.

2016

3550Background: Oxaliplatin/Fluoropyrimidine chemotherapy is an established adjuvant treatment for colon cancer (CC). Neurotoxicity from oxaliplatin is cumulative, dose limiting, and potentially ir...

Keywords:

Physical therapy
Adjuvant
Oxaliplatin
General surgery
Colorectal cancer
Medicine
Chemotherapy
adjuvant chemotherapy
non inferiority trial
Oncology
Internal medicine
Neurotoxicity
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations